Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today

We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Wednesday’s best-performing stocks.

Recursion Pharmaceuticals increased by 11.85 percent on Wednesday to end at $4.91 apiece as investors continued to gobble up shares after earning optimistic comments from an analyst.

In its latest episode of Mad Money, host and former hedge fund manager Jim Cramer gave a “buy” recommendation on the stock.

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today

A pharmacist in a hospital pharmacy stands next to a row of various drug containers.

“They do have an investment, and it’s a serious investment by Nvidia in them. I think, therefore, it’s a terrific [specification], and I would buy it,” Cramer said.

Additionally, Cramer posted confidence about the company following the Food and Drug Administration’s (FDA) earlier announcement to phase out animal testing requirements and shift to artificial intelligence.

“The AI company that has it … is Recursion Pharmaceuticals—RXRX—backed by Jensen Huang and Nvidia. And they’re going to be the winner in how we decide much faster to have drugs approved in this country,” he underscored.

Overall, RXRX ranks 4th on our list of Wednesday’s best-performing stocks. While we acknowledge the potential of RXRX, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RXRX and that has 10,000x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.